1. Suppressing Pancreatic Cancer Survival and Immune Escape via Nanoparticle-Modulated STING/STAT3 Axis Regulation.
- Author
-
Li R, Liu R, Xu Y, Zhang S, Yang P, Zeng W, Wang H, Liu Y, Yang H, Yue X, and Dai Z
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Signal Transduction drug effects, Tumor Escape drug effects, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal pathology, Cell Survival drug effects, Cell Proliferation drug effects, Liposomes chemistry, STAT3 Transcription Factor metabolism, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms immunology, Pancreatic Neoplasms pathology, Membrane Proteins metabolism, Nanoparticles chemistry
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) poses a challenge in oncology due to its high lethality and resistance to immunotherapy. Recently, emerging research on the stimulator of interferon gene (STING) pathway offers novel opportunities for immunotherapy. Although STING expression is retained in PDAC cells, the response of PDAC cells to STING agonists remains ineffective. Signal transducer and activator of transcription 3 (STAT3), a downstream pathway of STING, is notably overexpressed in pancreatic cancer and related to tumor survival and immune escape. We observed that inhibiting STAT3 signaling post-STING activation effectively suppressed tumor growth through signal transducer and activator of transcription 1 (STAT1)-mediated apoptosis but led to a potential risk of immune-related adverse events (irAEs). To address this issue, we designed a tumor-penetrating liposome for the codelivery of STING agonist and STAT3 inhibitor. These nanoparticles regulated the STING/STAT3 signaling axis and effectively inhibited the proliferation and survival of tumor. Simultaneously, we found a significant increase in the activation of NK cells and CD8
+ T cells after treatment, leading to robust innate immunity and adaptive immune response. We highlight the potential of regulating the STING/STAT3 axis as a promising treatment for improving clinical outcomes in PDAC patients.- Published
- 2024
- Full Text
- View/download PDF